This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon, Heinz: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.


Ameristar Casinos (ASCA) downgraded at Goldman from Neutral to Sell. Stock is up 44% year-to-date and the company is facing increased competition. $20 price target.

Cracker Barrel (CBRL - Get Report) downgraded at Argus from Buy to Hold. Company is seeing lower sales.

Cracker Barrel downgraded at BofA/Merrill from Buy to Underperform. Company is facing growth headwinds. $44 price target.

Dendreon (DNDN) rated new Buy at Goldman Sachs. $50 price target. Provenge is a potential blockbuster drug.

Devry (DV - Get Report) upgraded at BofA/Merrill to Buy. Gainful employment regulation was softened. $68 price target.

Education Management (EDMC) upgraded at BofA/Merrill from Underperform to Neutral, Bank of America/Merrill Lynch said. $24 price target. DOE has lessened its regulations on the for-profit group.

Express (EXPR - Get Report) rated new Buy at Brean Murray. $26 price target. Company can continue to expand margins, despite rising input costs.

General Mills (GIS - Get Report) downgraded at UBS from Buy to Neutral. Valuation call, based on a $41 price target.

Heinz (HNZ) upgraded at UBS from Neutral to Buy. $62 price target. Company can deliver above-consensus growth over the next several quarters.

Pharmasset (VRUS) rated new Buy at Brean Murray. $174 price target. Company is a market leader in what should become a top hepatitis C therapy.

End of report.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HNZ $72.49 0.00%
ASCA $0.00 0.00%
DNDN $0.06 -6.02%
CBRL $148.45 0.00%
DV $27.57 0.00%


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs